Sandoz International and its Switzerland-based subsidiary have been released from a patent infringement suit that aims to protect Genentech Inc.’s pulmonary fibrosis treatment from generic competition.

A Delaware federal judge on Thursday approved an agreement by San Francisco-based Genentech and Sandoz to dismiss the two entities, without prejudice, from the lawsuit, because neither had been involved in filing an abbreviated new drug application at the heart of the dispute.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]